Alx Oncology Holdings Inc.

ALXO Nasdaq SEC CIK 1810182
Follow Alx Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$21.8M +1.4% vs same quarter last year
EPS, diluted −$0.15 +63.4% vs same quarter last year
Operating cash flow −$14.7M +13.8% vs same quarter last year
Operating income −$22.9M −1.8% vs same quarter last year
Net income by quarter
−$29.2M
−$30.8M
−$25.9M
−$22.1M
−$22.8M
−$17.9M
−$18M
−$21.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$101.7M
FY24-−$134.9M
FY23-−$160.8M
FY22$0−$123.5M
FY21$0−$83.5M
FY20$1.2M−$45.7M
FY19$4.8M−$19.2M
FY18$2.1M−$13.7M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20−3694%−3869.7%
FY19−400%−401.2%
FY18−662%−664.3%
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$84.4M
FY24−$122.4M
FY23−$131.6M
FY22−$90.7M
FY21−$68.8M
FY20−$38.3M
FY19−$14.6M
FY18−$13.8M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Alx Oncology
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearAlx OncologyHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20−3869.7%−62.2%
FY19−401.2%−46.3%
FY18−664.3%−49.6%
FY17-−45.9%